Good morning, everyone, and nice to see you again. We hope the weekend was refreshing. As for us, we are back from a very brief respite, of sorts, and ready to resume the routine. As you know this calls for a cup or two of stimulation. We invite you, as always, to join us. And here is another invitation -
we are hosting a webinar on Biosimilars and the FDA today at 1 pm ET ( please see this). Meanwhile, here are some tidbits to get you going. Have a great day and do stay in touch...Warner Chilcott Is Considering A Sale (Bloomberg News)
Pfizer Claims BYU Tainted Jury Pool In Celebrex Case (Deseret News)
Glaxo Bid Undervalues Human Genome, Fund Manager Complains (Reuters)
FDA OKs J&J Levaquin Antibiotic To Combat Plague (Associated Press)
Novo Nordisk To Expand US Workforce By 15 Percent (Philadephia Inquirer)
Merck Patent On Zetia Is Ruled Valid (Reuters)
FDA Nixes Expanded Use For Amgen's Xgeva (Pharma Times)
FDA Approves Vivus Drug For Erectile Dysfunction (USA Today)
Pfizer May Unload Animal Health Unit In IPO (Bloomberg News)
Cuban Drugmaker Makes Medicines From Banana Peel (New York Daily News)
India To Press Japan For Access To Pharma Market (Economic Times)
Pakistan Expands Probe Into Ephedrine Scam (Dawn)
EDITOR'S NOTE: Please check this post for updates throughout the morning
sunrise pic thx to benimoto on flickr